Venture Medical LLC

Company reaffirms its commitment to patient access, clinical excellence, and responsible reimbursement reform under the new CMS framework.

New peer-reviewed study shows significant real-world improvement in pressure-ulcer healing with advanced cellular, acellular, and matrix-like products compared to standard care.

Venture Medical, LCC is sharing our position on the CY2026 Medicare Physician Fee Schedule and our future recommendations.

Venture Medical, LLC, a leader in advanced wound care solutions, today announced the closing of a strategic investment in Plasmacure B.V

This agreement will introduce a new technology that has already demonstrated strong results in promoting wound healing to the United States.

Partnership Focuses on Investigating the Use of CAMPS (Cellular, Acellular and Matrix-like Products) in Hard-to-Heal Pressure Ulcers